Capitol Health Limited

ASX:CAJ Stock Report

Market Cap: AU$405.1m

Capitol Health Valuation

Is CAJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAJ (A$0.37) is trading above our estimate of fair value (A$0.33)

Significantly Below Fair Value: CAJ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAJ?

Key metric: As CAJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CAJ. This is calculated by dividing CAJ's market cap by their current revenue.
What is CAJ's PS Ratio?
PS Ratio1.7x
SalesAU$234.82m
Market CapAU$405.11m

Price to Sales Ratio vs Peers

How does CAJ's PS Ratio compare to its peers?

The above table shows the PS ratio for CAJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
IDX Integral Diagnostics
1.4x6.6%AU$683.0m
HLA Healthia
1xn/aAU$252.1m
ACL Australian Clinical Labs
1x4.7%AU$697.5m
SLA SILK Laser Australia
1.8x9.1%AU$177.4m
CAJ Capitol Health
1.7x6.4%AU$405.1m

Price-To-Sales vs Peers: CAJ is expensive based on its Price-To-Sales Ratio (1.7x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does CAJ's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.61m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
CAJ 1.7xIndustry Avg. 1.4xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CAJ is expensive based on its Price-To-Sales Ratio (1.7x) compared to the Oceanic Healthcare industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is CAJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: CAJ is expensive based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.36
AU$0.32
-13.0%
4.8%AU$0.33AU$0.29n/a8
Nov ’25AU$0.36
AU$0.32
-11.8%
4.8%AU$0.33AU$0.29n/a8
Oct ’25AU$0.36
AU$0.31
-13.0%
6.0%AU$0.33AU$0.28n/a9
Sep ’25AU$0.32
AU$0.31
-0.5%
6.0%AU$0.33AU$0.28n/a9
Aug ’25AU$0.30
AU$0.29
-4.5%
8.2%AU$0.33AU$0.27n/a9
Jul ’25AU$0.30
AU$0.29
-2.9%
8.2%AU$0.33AU$0.27n/a9
Jun ’25AU$0.24
AU$0.29
+16.6%
7.4%AU$0.32AU$0.27n/a8
May ’25AU$0.24
AU$0.28
+15.7%
7.2%AU$0.32AU$0.27n/a7
Apr ’25AU$0.24
AU$0.28
+18.2%
7.2%AU$0.32AU$0.27n/a7
Mar ’25AU$0.27
AU$0.28
+4.1%
8.4%AU$0.32AU$0.25n/a7
Feb ’25AU$0.26
AU$0.27
+6.8%
7.5%AU$0.30AU$0.25n/a7
Jan ’25AU$0.23
AU$0.27
+14.7%
7.8%AU$0.30AU$0.24n/a8
Dec ’24AU$0.21
AU$0.27
+28.4%
7.8%AU$0.30AU$0.24n/a8
Nov ’24AU$0.19
AU$0.27
+43.2%
6.7%AU$0.30AU$0.25AU$0.368
Oct ’24AU$0.21
AU$0.28
+31.1%
7.0%AU$0.30AU$0.25AU$0.369
Sep ’24AU$0.23
AU$0.29
+27.4%
13.6%AU$0.39AU$0.25AU$0.3210
Aug ’24AU$0.23
AU$0.30
+29.8%
10.4%AU$0.39AU$0.27AU$0.3010
Jul ’24AU$0.27
AU$0.31
+16.5%
10.4%AU$0.39AU$0.28AU$0.3011
Jun ’24AU$0.28
AU$0.33
+17.5%
9.4%AU$0.39AU$0.28AU$0.2410
May ’24AU$0.28
AU$0.33
+19.6%
9.9%AU$0.39AU$0.28AU$0.249
Apr ’24AU$0.27
AU$0.33
+23.0%
10.8%AU$0.39AU$0.28AU$0.249
Mar ’24AU$0.27
AU$0.33
+23.1%
11.1%AU$0.39AU$0.28AU$0.278
Feb ’24AU$0.28
AU$0.39
+36.4%
10.9%AU$0.43AU$0.31AU$0.267
Jan ’24AU$0.32
AU$0.39
+21.5%
10.9%AU$0.43AU$0.31AU$0.237
Dec ’23AU$0.32
AU$0.39
+23.0%
11.2%AU$0.43AU$0.31AU$0.216
Nov ’23AU$0.33
AU$0.40
+21.8%
13.5%AU$0.48AU$0.31AU$0.196

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Doctor Care Anywhere Group

AU$23.8m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

7D

-5.9%

1Y

36.2%

Nova Eye Medical

AU$33.2m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.14

7D

-3.3%

1Y

11.5%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

7D

-12.5%

1Y

n/a